Actively Recruiting
ADSCs Therapy in Patients With CTD-ILD
Led by China Medical University Hospital · Updated on 2026-05-13
16
Participants Needed
1
Research Sites
171 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Connective tissue disease (CTD), an autoimmune and inflammatory disease, usually accompanied by lung interstitial/alveolar inflammation and fibrosis (so called interstitial lung disease, ILD). The prevalence and mortality rate of CTD-ILD increase in recent several years. Although the use of corticosteroids and strong immunosuppressants can improve ILD in some patients with CTD, progressive lung fibrosis which needs lung transplantation and results in respiratory failure, even with mortality is observed. Currently, stem cell therapy is a breakthrough in the treatment of CTD-ILD, and the effective therapy with stem cells for patients with ILD have been reported.
CONDITIONS
Official Title
ADSCs Therapy in Patients With CTD-ILD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged between 20 and 80 years
- Diagnosed with connective tissue diseases such as dermatomyositis, polymyositis, scleroderma, systemic lupus erythematosus, rheumatoid arthritis, or Sjogren's syndrome
- Have refractory or progressive fibrotic interstitial lung disease despite more than 24 months of steroid and immunosuppressant treatment with worsening lung function or lung lesions
- Or have rapidly progressive interstitial lung disease treated with high-dose steroids and immunosuppressants for more than 3 months with continued lung deterioration
- Or have rapidly worsening pulmonary symptoms within one month with worsening breathing and oxygen levels
- Have a well-established family support system confirmed by interviews
- Have a negative high-sensitivity urine pregnancy test before the trial
- Agree to use effective contraception during the trial
You will not qualify if you...
- Unwilling to sign informed consent after detailed explanation
- Younger than 20 or older than 80 years with improving lung function or lung lesions after 6 months of treatment
- Pregnant, breastfeeding, or women of childbearing age not using contraception
- Abnormal liver function (GOT and GPT more than twice upper limit except due to inflammatory myopathy) or poor kidney function (creatinine over 1.4 units)
- Have immune deficiencies such as HIV/AIDS or other specific notifiable infectious diseases
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
China Medical University Hospital
Taichung, Taiwan, 404327
Actively Recruiting
Research Team
D
Der-Yuan Chen, M.D.;Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here